Kiniksa Pharmaceuticals
KNSA
134 hedge funds and large institutions have $606M invested in Kiniksa Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 49 increasing their positions, 43 reducing their positions, and 11 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
73% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 11
35% more capital invested
Capital invested by funds: $448M → $606M (+$158M)
14% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 43
13% more call options, than puts
Call options by funds: $5.21M | Put options by funds: $4.6M
8.04% more ownership
Funds ownership: 90.92% → 98.97% (+8%)
6% more funds holding
Funds holding: 127 → 134 (+7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$29.8M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$8.49M |
| 3 |
Goldman Sachs
New York
|
+$8.33M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$7.58M |
| 5 |
Millennium Management
New York
|
+$4.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$6.36M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$6.1M |
| 3 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$5.15M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$5.07M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$4.08M |
KNSA Hedge Fund Activity: Q3 2023 in Review
134 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q3 2023, worth a combined $606M — up 35% from $448M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new KNSA positions and 11 closed out — a net gain of 8 holders — while 49 added to existing stakes and 43 trimmed.
The largest buyer was Fairmount Funds Management, adding an estimated $29.8M. The largest seller was Hudson Bay Capital Management, cutting an estimated $6.36M.
- 134 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q3 2023, up from 127 in Q2 2023.
- Funds reported $606M of Kiniksa Pharmaceuticals stock for Q3 2023, up 35% quarter-over-quarter.
- 19 funds opened new Kiniksa Pharmaceuticals positions in Q3 2023 and 11 closed out, a net change of +8 holders.
- The largest Kiniksa Pharmaceuticals buyer in Q3 2023 was Fairmount Funds Management, an estimated $29.8M added.
- The largest Kiniksa Pharmaceuticals seller in Q3 2023 was Hudson Bay Capital Management, an estimated $6.36M sold.
Based on aggregated 13F filings for Q3 2023.